Investigational Drug Information for Epacadostat
✉ Email this page to a colleague
What is the drug development status for Epacadostat?
Epacadostat is an investigational drug.
There have been 56 clinical trials for Epacadostat.
The most recent clinical trial was a Phase 3 trial, which was initiated on June 21st 2016.
The most common disease conditions in clinical trials are Carcinoma, Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Incyte Corporation, Merck Sharp & Dohme Corp., and National Cancer Institute (NCI).
There are sixty-four US patents protecting this investigational drug and zero international patents.
Summary for Epacadostat
| US Patents | 64 |
| International Patents | 1,358 |
| US Patent Applications | 599 |
| WIPO Patent Applications | 638 |
| Japanese Patent Applications | 167 |
| Clinical Trial Progress | Phase 3 (2016-06-21) |
| Vendors | 61 |
Recent Clinical Trials for Epacadostat
| Title | Sponsor | Phase |
|---|---|---|
| An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma | Incyte Corporation | Phase 2 |
| Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. | European Network for Gynaecological Oncological Trial groups(ENGOT) | Phase 2 |
| Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. | GOG Foundation | Phase 2 |
Clinical Trial Summary for Epacadostat
Top disease conditions for Epacadostat
Top clinical trial sponsors for Epacadostat
US Patents for Epacadostat
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Epacadostat | ⤷ Sign Up | Synergistic combination of immunologic inhibitors for the treatment of cancer | The University of Chicago (Chicago, IL) | ⤷ Sign Up |
| Epacadostat | ⤷ Sign Up | Tank-binding kinase inhibitor compounds | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Sign Up |
| Epacadostat | ⤷ Sign Up | Heterocyclic compounds as PI3K-.gamma. inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Sign Up |
| Epacadostat | ⤷ Sign Up | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign Up |
| Epacadostat | ⤷ Sign Up | Heterocyclic amides useful as protein modulators | GlaxoSmithKline Intellectual Property Development Limited (GB) | ⤷ Sign Up |
| Epacadostat | ⤷ Sign Up | Solid forms of a toll-like receptor modulator | GILEAD SCIENCES, INC. (Foster City, CA) | ⤷ Sign Up |
| Epacadostat | ⤷ Sign Up | Inhibitors of indoleamine 2,3-dioxygenase | GlaxoSmithKline Intellectual Property Development Limited (Brentford, Middlesex, GB) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Epacadostat
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Epacadostat | Argentina | AR072490 | 2028-07-08 | ⤷ Sign Up |
| Epacadostat | Australia | AU2009268739 | 2028-07-08 | ⤷ Sign Up |
| Epacadostat | Australia | AU2014210662 | 2028-07-08 | ⤷ Sign Up |
| Epacadostat | Australia | AU2016204914 | 2028-07-08 | ⤷ Sign Up |
| Epacadostat | Australia | AU2018200457 | 2028-07-08 | ⤷ Sign Up |
| Epacadostat | Australia | AU2018267589 | 2028-07-08 | ⤷ Sign Up |
| Epacadostat | Australia | AU2020239772 | 2028-07-08 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
